Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emmaus Life Sciences, Inc.MYND · Entity 205 | Director | October 08, 2018 | October 11, 2018 |
| Telemynd, Inc.NONE · Entity 155932 | Director | July 16, 2019 | July 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emmaus Life Sciences, Inc.
Report date October 08, 2018 · Filed October 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 126,627 |
Reported balance
After 2018-10-08 transaction · row 1
1 source rowRow 1 · 2018-10-08 · Grant · Acquired 30,000 · Balance 126,627 F1: The above restricted shares were granted under Mynd Analytics, Inc.'s (the "Company") Amended and Restated 2012 Omnibus Incentive Compensation Plan and vest quarterly. |
Filing footnotes · ownership attribution and instrument terms
F1: The above restricted shares were granted under Mynd Analytics, Inc.'s (the "Company") Amended and Restated 2012 Omnibus Incentive Compensation Plan and vest quarterly.
Telemynd, Inc.
Report date July 16, 2019 · Filed July 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,627 |
Reported balance
After 2019-07-16 transaction · row 1
1 source rowRow 1 · 2019-07-16 · Other · Acquired 126,627 · Balance 126,627 F1: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd. |
| Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 50,000 |
Reported balance
After 2019-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-16 · Other · Acquired 50,000 · Balance 50,000 F2: The reporting person received his shares of Series A Preferred Stock pursuant to an Exchange Agreement with MYnd and Telemynd under which he exchanged previously held securities for shares of Series A Preferred Stock. F3: The shares of Series A Preferred Stock have no expiration date and are convertible at any time at the election of the Reporting Person without payment of further consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd.
F2: The reporting person received his shares of Series A Preferred Stock pursuant to an Exchange Agreement with MYnd and Telemynd under which he exchanged previously held securities for shares of Series A Preferred Stock.
F3: The shares of Series A Preferred Stock have no expiration date and are convertible at any time at the election of the Reporting Person without payment of further consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2019 Filed Jul 18, 2019 18:51 UTC | Telemynd, Inc. NONE · Entity 155932 | OtherSeries A Preferred Stock · Derivative | 50,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001213900-19-013145 · ownership.xml · derivative · entry 2 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: The reporting person received his shares of Series A Preferred Stock pursuant to an Exchange Agreement with MYnd and Telemynd under which he exchanged previously held securities for shares of Series A Preferred Stock. F2 · price: The reporting person received his shares of Series A Preferred Stock pursuant to an Exchange Agreement with MYnd and Telemynd under which he exchanged previously held securities for shares of Series A Preferred Stock. F3 · derivative.exercise_date: The shares of Series A Preferred Stock have no expiration date and are convertible at any time at the election of the Reporting Person without payment of further consideration. F3 · derivative.expiration_date: The shares of Series A Preferred Stock have no expiration date and are convertible at any time at the election of the Reporting Person without payment of further consideration. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 18:51 UTC | Telemynd, Inc. NONE · Entity 155932 | OtherCommon Stock | 126,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-013145 · ownership.xml · nonDerivative · entry 1 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,627 F1 · shares: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd. F1 · price: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd. Read SEC document |
| October 08, 2018 Filed Oct 11, 2018 00:07 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantCOMMON STOCK | 30,000 | $1.38 | $41,400.00 |
DisclosureSEC source: 0001615774-18-010693 · s113209_form4.xml · nonDerivative · entry 1 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,627 F1 · shares: The above restricted shares were granted under Mynd Analytics, Inc.'s (the "Company") Amended and Restated 2012 Omnibus Incentive Compensation Plan and vest quarterly. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:05 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantCommon Stock Purchase Warrant · Derivative | 27,027 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001615774-18-010012 · s112893_form4.xml · derivative · entry 2 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,027 Underlying: Common Stock · 27,027 shares Expires 2023-09-23 F2 · price: Reporting Person purchased 27,027 units at a price of $1.85 per unit, with each unit consisting of (i) one share of Common Stock and (ii) one Common Stock Purchase Warrant to purchase one share of Common Stock for $2.00 per share. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:05 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantCommon Stock | 27,027 | $1.85 | $49,999.95 |
DisclosureSEC source: 0001615774-18-010012 · s112893_form4.xml · nonDerivative · entry 1 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,627 F1 · security: 27,027 shares of Common Stock and Warrants to purchase 27,027 shares of Common Stock for $2.00 were purchased by the Reporting Person for an aggregate of $50,000 pursuant to a Subscription Agreement, dated September 21, 2018 (the "Subscription Agreement"), between the Issuer and the investors party thereto. Read SEC document |
| May 25, 2018 Filed May 31, 2018 00:27 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantCommon Stock | 4,500 | $2.27 | $10,215.00 |
DisclosureSEC source: 0001615774-18-004582 · s110527_form4.xml · nonDerivative · entry 1 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,600 F1 · shares: On May 25, 2018, the Board of Directors (the "Board") of MYnd Analytics, Inc. granted the indicated number of restricted shares (the "Shares") in lieu of the remaining amount of the Reporting Person's Board fee for the 2017-2018 fiscal year. The Shares were issued pursuant to the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 23:18 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantWarrant · Derivative | 50,000 | $6,250.00 Strike: $2.34 | $312,500,000.00 |
DisclosureSEC source: 0001615774-18-002321 · s109515_form4.xml · derivative · entry 2 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: 50,000 shares of Series A Preferred Stock and Warrants to purchase 50,000 shares of Common Stock were purchased by the Reporting Person for an aggregate of $100,000 pursuant to a Subscription Agreement, dated as of March 29, 2018 (the "Subscription Agreement"), between the Issuer and the investors party thereto. The Series A Preferred Stock are convertible by the Reporting Person as of the date of the Subscription Agreement and are convertible at a conversion price of $1.875 per share. F3 · derivative.exercise_price: Each Warrant entitles its holder to purchase one share of Common Stock at an exercise price of $2.34 per share, subject to adjustment, at any time commencing on March 29, 2018 and expiring on March 29, 2023 (or earlier upon redemption or liquidation). F3 · derivative.exercise_date: Each Warrant entitles its holder to purchase one share of Common Stock at an exercise price of $2.34 per share, subject to adjustment, at any time commencing on March 29, 2018 and expiring on March 29, 2023 (or earlier upon redemption or liquidation). F3 · derivative.expiration_date: Each Warrant entitles its holder to purchase one share of Common Stock at an exercise price of $2.34 per share, subject to adjustment, at any time commencing on March 29, 2018 and expiring on March 29, 2023 (or earlier upon redemption or liquidation). Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 23:18 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantSeries A Preferred Stock · Derivative | 50,000 | $93,750.00 Strike: $1.88 | $4,687,500,000.00 |
DisclosureSEC source: 0001615774-18-002321 · s109515_form4.xml · derivative · entry 1 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: 50,000 shares of Series A Preferred Stock and Warrants to purchase 50,000 shares of Common Stock were purchased by the Reporting Person for an aggregate of $100,000 pursuant to a Subscription Agreement, dated as of March 29, 2018 (the "Subscription Agreement"), between the Issuer and the investors party thereto. The Series A Preferred Stock are convertible by the Reporting Person as of the date of the Subscription Agreement and are convertible at a conversion price of $1.875 per share. F1 · shares: 50,000 shares of Series A Preferred Stock and Warrants to purchase 50,000 shares of Common Stock were purchased by the Reporting Person for an aggregate of $100,000 pursuant to a Subscription Agreement, dated as of March 29, 2018 (the "Subscription Agreement"), between the Issuer and the investors party thereto. The Series A Preferred Stock are convertible by the Reporting Person as of the date of the Subscription Agreement and are convertible at a conversion price of $1.875 per share. F2 · shares: Each Share of Series A Preferred Stock is convertible, at the holder's option at any time, initially into 50,000 shares of the Issuer's Common Stock, subject to specific adjustments and limitations as set forth in the Certificate of Designation pertaining to such Series A Preferred Stock. F2 · price: Each Share of Series A Preferred Stock is convertible, at the holder's option at any time, initially into 50,000 shares of the Issuer's Common Stock, subject to specific adjustments and limitations as set forth in the Certificate of Designation pertaining to such Series A Preferred Stock. F2 · derivative.exercise_date: Each Share of Series A Preferred Stock is convertible, at the holder's option at any time, initially into 50,000 shares of the Issuer's Common Stock, subject to specific adjustments and limitations as set forth in the Certificate of Designation pertaining to such Series A Preferred Stock. F2 · derivative.expiration_date: Each Share of Series A Preferred Stock is convertible, at the holder's option at any time, initially into 50,000 shares of the Issuer's Common Stock, subject to specific adjustments and limitations as set forth in the Certificate of Designation pertaining to such Series A Preferred Stock. F1 · derivative.underlying_shares: 50,000 shares of Series A Preferred Stock and Warrants to purchase 50,000 shares of Common Stock were purchased by the Reporting Person for an aggregate of $100,000 pursuant to a Subscription Agreement, dated as of March 29, 2018 (the "Subscription Agreement"), between the Issuer and the investors party thereto. The Series A Preferred Stock are convertible by the Reporting Person as of the date of the Subscription Agreement and are convertible at a conversion price of $1.875 per share. F2 · derivative.underlying_shares: Each Share of Series A Preferred Stock is convertible, at the holder's option at any time, initially into 50,000 shares of the Issuer's Common Stock, subject to specific adjustments and limitations as set forth in the Certificate of Designation pertaining to such Series A Preferred Stock. Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 21:19 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | PurchaseCommon Stock | 15,000 | $3.65 | $54,735.00 |
DisclosureSEC source: 0001615774-17-007165 · s108366_form4.xml · nonDerivative · entry 1 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Read SEC document |
| September 19, 2017 Filed Sep 22, 2017 00:21 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantDirector Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001615774-17-005261 · s107567_form4.xml · derivative · entry 2 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-09-19 F1 · derivative.exercise_date: The option vests in four equal quarterly installments beginning on December 19, 2017. Read SEC document |
| September 19, 2017 Filed Sep 22, 2017 00:21 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-17-005261 · s107567_form4.xml · nonDerivative · entry 1 Unanue Peter · CIK 0001717633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,100 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.